Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial
Franck Morschhauser(Université de Lille), Hervé Tilly(Inserm), Aristeidis Chaidos(Hammersmith Hospital), Pam McKay(Beatson West of Scotland Cancer Centre), Tycel Phillips(University of Michigan–Ann Arbor), Sarit Assouline(McGill University), Connie Lee Batlevi(Memorial Sloan Kettering Cancer Center), Phillip L. Campbell(Barwon Health), Vincent Ribrag(Institut Gustave Roussy), Gandhi Damaj(Université de Caen Normandie), Michael Dickinson(The Royal Melbourne Hospital), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Maciej Kazmierczak(Poznan University of Medical Sciences), Stephen Opat(Monash University), John Radford(University of Manchester), Anna Schmitt(Institut Bergonié), Jay Yang(Epizyme (United States)), Jennifer Whalen(Epizyme (United States)), Shefali Agarwal(Epizyme (United States)), Deyaa Adib(Epizyme (United States)), Gilles Salles(Université Claude Bernard Lyon 1)
Cited by 581Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis